What intervention trials don't tell us: the residual risk in primary prevention

Area of Science:

• Cardiology
• Lipidology
• Preventive Medicine

Background:

• Despite achieving target low-density lipoprotein (LDL)-cholesterol levels, a significant portion of individuals remain at risk for cardiovascular events.
• Residual cardiovascular risk is associated with lipid abnormalities beyond LDL-cholesterol, including low high-density lipoprotein (HDL)-cholesterol and elevated triglycerides.

Purpose of the Study:

• To evaluate the role of non-LDL-C lipid abnormalities in cardiovascular prognosis.
• To assess the efficacy of interventions targeting these residual lipid risks in primary and secondary prevention.

Main Methods:

• Review of epidemiological studies and intervention clinical trials.
• Analysis of data concerning lipid profiles, including LDL-C, HDL-C, triglycerides, apolipoprotein B, and non-HDL cholesterol.
• Examination of outcomes from recent drug trials aimed at modifying HDL-C and triglycerides.

Main Results:

• Current evidence suggests that normalizing non-LDL-C lipid parameters may not definitively reduce clinical events, particularly in primary prevention.
• Recent trials targeting HDL-C or triglycerides in patients on statin therapy have not shown a significant favorable impact on secondary prevention outcomes.
• Robust evidence is lacking for the benefit of these interventions in lower-risk populations undergoing primary prevention.

Conclusions:

• The clinical benefit of addressing residual lipid risk factors (low HDL-C, high triglycerides) remains controversial, especially in primary prevention.
• Further research into novel, safe, and effective drugs for managing these lipid abnormalities is ongoing.
• Current strategies to mitigate cardiovascular risk primarily rely on lifestyle modifications and statin therapy.